Avalo Therapeutics (AVTX) Total Non-Current Liabilities (2015 - 2026)
Avalo Therapeutics (AVTX) posted Total Non-Current Liabilities of $31.6 million for Q1 2026, down 5.42% on a QoQ basis from $33.4 million in Q4 2025, and up 286.45% year-over-year from $8.2 million in Q1 2025.
Avalo Therapeutics (AVTX) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
Avalo Therapeutics' Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $31.6 million for Q1 2026.
- Quarterly Total Non-Current Liabilities rose 286.45% year-over-year to $31.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.6 million (up 286.45% YoY) and the FY2025 annual result came in at $33.4 million, up 261.97% from the prior year.
- Total Non-Current Liabilities was $31.6 million for Q1 2026 at Avalo Therapeutics, down from $33.4 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $219.1 million in Q1 2024 and bottomed at $8.1 million in Q4 2023.
- A 5-year average of $43.8 million and a median of $33.4 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities jumped 436.16% — and 2025, when it sank 96.27%.
- Avalo Therapeutics' Total Non-Current Liabilities stood at $39.5 million in 2022, then slumped by 79.37% to $8.1 million in 2023, then advanced by 13.28% to $9.2 million in 2024, then surged by 261.97% to $33.4 million in 2025, then dropped by 5.42% to $31.6 million in 2026.
- Business Quant data shows AVTX's Total Non-Current Liabilities at $31.6 million in Q1 2026, $33.4 million in Q4 2025, and $10.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | 31.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.57 Mn |
| Dec 31, 2025 | 33.37 Mn |
| Sep 30, 2025 | 10.39 Mn |
| Jun 30, 2025 | 11.75 Mn |
| Mar 31, 2025 | 8.17 Mn |
| Dec 31, 2024 | 9.22 Mn |
| Sep 30, 2024 | 63.91 Mn |
| Jun 30, 2024 | 99.75 Mn |
| Mar 31, 2024 | 219.14 Mn |
| Dec 31, 2023 | 8.14 Mn |
| Sep 30, 2023 | 13.12 Mn |
| Jun 30, 2023 | 29.66 Mn |
| Mar 31, 2023 | 40.87 Mn |
| Dec 31, 2022 | 39.45 Mn |
| Sep 30, 2022 | 36.78 Mn |
| Jun 30, 2022 | 36.24 Mn |
| Mar 31, 2022 | 53.20 Mn |
| Dec 31, 2021 | 57.13 Mn |
| Sep 30, 2021 | 53.65 Mn |
| Jun 30, 2021 | 40.94 Mn |